INHALED TRIPLE THERAPY IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: TRIBUTE CLINICAL STUDY DATA

Abstract

Chronic obstructive pulmonary disease (COPD) is characterised by persistent respiratory symptoms and airflow limitation. Due to disease severity, exacerbations, exacerbations, affecting the quality of life, become more frequent, accelerate the progression of the disease. Dual therapy is often insufficient to reduce frequency of COPD exacerbation. Treatment with three different pharmacotherapeutic groups of inhaled medications is superior to dual bronchodilator therapy (TRIBUTE clinical study data): a significant reduction in the moderate-to-severe COPD exacerbations. It was observed improvement of health-related quality of life, lung function, without differences in safety profile. Also, in the analysis of the results, it was observed that BDP / FF / G treatment was particularly effective in the presence of chronic bronchitis COPD phenotype with elevated peripheral blood eosinophil (>2%). Such treatment is promising for long-term treatment of COPD in carefully selected patients.